SCHEMBL6284875

SCHEMBL6284875

[CH2]N(C)CC(O)c1cc2ccccc2o1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2D6 P10635 1/20 0.55
HIF1A Q16665 1/20 0.55
HPGD P15428 2/20 0.41
ALDH1A1 P00352 2/20 0.41
MAOB P27338 2/20 0.39
AOC3 Q16853 1/20 0.39
HSD17B10 Q99714 3/20 0.39
KDM4E B2RXH2 2/20 0.39
FLT3 P36888 1/20 0.39
LOXL2 Q9Y4K0 1/20 0.39
MGLL Q99685 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
MKNK1 Q9BUB5 2/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
KMT2A Q03164 2/20 0.38
TYR P14679 1/20 0.38
DAO P14920 1/20 0.38
AKR1B1 P15121 1/20 0.38
MEN1 O00255 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6284878 0.89 CYP2D6 (0.56) CYP2D6HIF1AHPGDALDH1A1MAOB
SCHEMBL8583896 0.83 CYP2D6 (0.54) CYP2D6HIF1AHPGDALDH1A1MAOB
SCHEMBL24173635 0.80 CYP2D6 (0.60) CYP2D6HIF1AHPGDALDH1A1MAOB
SCHEMBL29172969 0.80 CYP2D6 (0.60) CYP2D6HIF1AHPGDALDH1A1MAOB
SCHEMBL6612005 0.76 CYP2D6 (0.56) CYP2D6HIF1AHPGDMAOBHSD17B10
SCHEMBL6622018 0.76 CYP2D6 (0.56) CYP2D6HIF1AHPGDMAOBHSD17B10
SCHEMBL6610235 0.76 CYP2D6 (0.56) CYP2D6HIF1AHPGDMAOBHSD17B10
SCHEMBL8158785 0.76 CYP2D6 (0.56) CYP2D6HIF1AHPGDALDH1A1MAOB
SCHEMBL6610233 0.75 CYP2D6 (0.60) CYP2D6HIF1AALDH1A1MAOBHSD17B10
SCHEMBL6608279 0.75 CYP2D6 (0.60) CYP2D6HIF1AALDH1A1MAOBHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6878705-B2 4-oxo-4,7-dihydrofuro[2,3-b]pyridine-5-carboxamide antiviral agents PFIZER (US) 2005-04-12 US disclosed
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY 2004-12-23 US disclosed
EP-1465895-A2 4-OXO-4,7-DIHYDROFURO(2,3-B)PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-10-13 EP disclosed
WO-2003059911-A2 4-OXO-4, 7-DIHYDROFURO[2,3-b]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-07-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040259907-A1 4-OXO-4,7-DIHYDROFURO[2,3-B]PYRIDINE-5-CARBOXAMIDE ANTIVIRAL AGENTS IL4, ZC3HAV1, IRF3 CYP2D6 692/4885HIF1A 1232/4885HPGD 2463/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.